The US Food and Drug Administration (FDA) has approved a new drug, Daraxonrasib, which has been shown to significantly extend survival times for patients with advanced pancreatic cancer. The approval follows a large clinical trial in which patients taking Daraxonrasib lived an average of 13.2 months, nearly double the 6.7 months observed among those receiving standard chemotherapy.

Daraxonrasib is intended for patients with metastatic pancreatic cancer—cancer that has spread beyond the pancreas—who have already undergone chemotherapy. The drug represents a major development in treating this aggressive disease, which has a poor prognosis and limited treatment options.

The decision by the FDA to approve Daraxonrasib has prompted advocacy groups in the United Kingdom to call for swift access to the drug through the National Health Service (NHS). Pancreatic Cancer UK, a leading charity dedicated to supporting patients and research, highlighted the approval as one of the most significant advances in pancreatic cancer treatment in decades. Diana Jupp, the charity's chief executive, emphasized the potential of the drug to provide hope to patients worldwide.

Pancreatic cancer remains a major public health challenge in the UK, with approximately 11,500 new cases diagnosed annually and around 10,200 deaths each year, making it the fifth leading cause of cancer-related mortality.

Regulatory bodies in the UK, including the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE), have been approached for comment regarding potential approval and availability of Daraxonrasib within the NHS. The development raises prospects for improved outcomes in a disease where treatment options have historically been limited and survival rates low.